Exelixis Inc. (EXEL) and Gilead Sciences Inc. (GILD) are set to release their Q4 financial results after market hours on February 10. Exelixis has seen a stock increase of 30% over the past year, while Gilead’s shares have risen by nearly 60%. Exelixis expects Q4 earnings per share (EPS) to rise 40% to $0.77, with sales anticipated at $584.68 million, a year-over-year increase of 3%. Gilead’s Q4 sales are expected to remain flat at $7.57 billion, with a projected EPS dip of 3% to $1.83.
Exelixis recently received FDA acceptance for a New Drug Application for a combination therapy targeting metastatic colorectal cancer, which is anticipated to expand their revenue streams. Meanwhile, Gilead’s primary growth driver remains its HIV product Biktarvy, alongside a robust R&D pipeline. For fiscal 2025, Exelixis is expected to achieve an annual EPS growth of 48% to $2.96, while Gilead’s EPS is projected to increase 76% to $8.14 per share.
